- Home
- URGN vs NETD Comparison
URGN vs NETD Comparison
Compare URGN & NETD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- NETD
- Stock Information
- Founded
- URGN 2004
- NETD 2023
- Country
- URGN United States
- NETD United States
- Employees
- URGN N/A
- NETD N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- NETD
- Sector
- URGN Health Care
- NETD
- Exchange
- URGN Nasdaq
- NETD Nasdaq
- Market Cap
- URGN 465.9M
- NETD 417.9M
- IPO Year
- URGN 2017
- NETD 2023
- Fundamental
- Price
- URGN $10.63
- NETD $10.94
- Analyst Decision
- URGN Strong Buy
- NETD
- Analyst Count
- URGN 6
- NETD 0
- Target Price
- URGN $40.75
- NETD N/A
- AVG Volume (30 Days)
- URGN 419.1K
- NETD 125.4K
- Earning Date
- URGN 03-10-2025
- NETD 01-01-0001
- Dividend Yield
- URGN N/A
- NETD N/A
- EPS Growth
- URGN N/A
- NETD N/A
- EPS
- URGN N/A
- NETD N/A
- Revenue
- URGN $90,398,000.00
- NETD N/A
- Revenue This Year
- URGN $43.60
- NETD N/A
- Revenue Next Year
- URGN $103.77
- NETD N/A
- P/E Ratio
- URGN N/A
- NETD $34.90
- Revenue Growth
- URGN 9.29
- NETD N/A
- 52 Week Low
- URGN $9.03
- NETD $10.41
- 52 Week High
- URGN $20.70
- NETD $11.10
- Technical
- Relative Strength Index (RSI)
- URGN 44.41
- NETD 47.03
- Support Level
- URGN $11.12
- NETD $10.95
- Resistance Level
- URGN $11.91
- NETD $11.01
- Average True Range (ATR)
- URGN 0.56
- NETD 0.03
- MACD
- URGN -0.07
- NETD -0.01
- Stochastic Oscillator
- URGN 3.87
- NETD 0.00
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About NETD Nabors Energy Transition Corp. II
Nabors Energy Transition Corp II is a blank check company.